RPT-FACTBOX-Top 5 overseas Japanese drug M&A deals

(Repeats to tabulate)

Sept 3 (Reuters) - Japan's Dainippon Sumitomo Pharma Co Ltd
(4506.T) said it agreed to buy U.S. drugmaker Sepracor Inc
SEPR.O for around $2.6 billion. [ID:nT42454]

The deal is the fourth-biggest overseas buy by a Japanese
drugmaker, and follows recent acquisitions, primarily in the
United States, as Japanese firms seek to grow their drug
pipelines and raise their profile in the world's largest
pharmaceuticals market.

TOP 5 OUTBOUND JAPAN DRUG M&A DATE TARGET
BUYER VALUE 2008 Millennium Pharma
Takeda Pharma (4502.T) $8.9 bln 2008 Ranbaxy Labs
(RANB.BO) Daiichi Sankyo (4568.T) $5 bln * 2008 MGI Pharma

Eisai Co Ltd (4523.T) $3.9 bln 2009 Sepracor
Inc SEPR.O Dainippon Sumitomo (4506.T) $2.6 bln 2008 Sciele
Pharma Inc Shionogi & Co Ltd (4507.T) $1.1 bln

* includes $3.4 bln acquisition of 43 percent stake and
$1.6 bln private placement

Other recent deals include:

July 2009 - Hisamitsu Pharmaceutical Co (4530.T) says to
pay $430 million for Miami-based Noven Pharmaceuticals Inc
(NOVN.O)

May 2008 - Takeda buys U.S.-based IDM Pharma (IDMI.O) for
$75 million.

March 2009 - Sekisui Chemical Co Ltd (4204.T) to acquire
American Diagnostica Inc for $51 million.

... and two that got away:

March 2009 - Astellas Pharma Inc (4503.T) withdraws a $1
billion bid for CV Therapeutics CVTX.O

July 2009 - Shionogi scraps plans for its Sciele Pharma
unit to buy privately-held U.S. firm Victory Pharma for $150
million.
(Compiled by Asia desk +65 6870 3835)
(If you have a query or comment on this story, send an email
to news.feedback.asia@thomsonreuters.com)